Platform Specialty Products Corporation Announces Fourth

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Platform Specialty Products Corporation Announces Fourth Quarter and Full Year 2014 Financial Results

-   2014 Net sales reach $843 million representing 13.0% growth over combined prior year sales

-  2014 adjusted EBITDA rises 17.8% to $212 million representing organic growth of 9%  

-    Adjusted EBITDA margin for 2014 of 25.2% with MacDermid delivering a record for the business

-    Revising Ag integration synergy estimates up to $80 million from $65 million

MIAMI, March 18, 2015 (GLOBE NEWSWIRE) -- Platform Specialty Products Corporation (NYSE: PAH ) ("Platform" or "the Company"), a global, diversified specialty chemicals company, today announced its financial results for the three and twelve months ended December 31, 2014.

Please note: the 2013 as reported quarterly and year-to-date information is based on the predecessor information of MacDermid, Incorporated ("MacDermid") and does not reflect the purchase accounting effect of Platform's acquisition of MacDermid in October 2013. In order to perform a proper comparison of the P&L between 2013 and 2014, the Company has made certain adjustments to its reported numbers, as detailed in the financial tables included in this press release. The Company believes that this "as adjusted" format provides a more complete understanding of its operational results and a meaningful comparison of its performance between periods.

For the three months ended December 31, 2014:

  • Net sales for the quarter increased 47.7% to $273.6 million compared to $185.3 million in the fourth quarter of 2013. On an organic basis, MacDermid's net sales of $185.6 million were up slightly year-over-year despite facing a $5 million foreign exchange headwind as a result of the strengthening U.S. dollar.
  • Reported net loss increased to ($266.7) million, compared to ($200.1) million for the same period in 2013. MacDermid's net loss decreased to ($10.1) million, compared to ($205.2) million in the same period in 2013.
  • Reported diluted earnings per share was ($1.59).
  • Adjusted EBITDA for the quarter rose 47.6% to $65.7 million compared to $44.5 million from the year-prior period. Excluding the impact of the AgroSolutions segment, adjusted EBITDA increased by 11.7% to $49.7 million, including an adverse foreign exchange impact of approximately $1.4 million.
  • Adjusted EBITDA margin levels were 24.0% for both quarters in 2014 and 2013. Adjusted EBITDA margin for the MacDermid business was 26.7%, representing a record level.
  • Adjusted net income attributable to common shareholders rose to $27.8 million in this quarter from $22.0 million in the fourth quarter of 2013.
  • Adjusted diluted earnings per share were $0.14, compared to $0.11 per adjusted diluted earnings per share in the same period of 2013.
  • Adjusted recurring free cash flow of $67.8 million, or $0.35 per adjusted diluted share, was 63.4% higher for this fourth quarter 2014 compared to the $41.5 million, or $0.21 per adjusted diluted share, reported in the fourth quarter of 2013.

For the twelve months ended December 31, 2014 :

  • Net sales for the full year 2014 rose 13.0% to $843.2 million compared to $746 million in 2013. On an organic basis, net sales from MacDermid rose 1.2% to $755.2 million.
  • Reported net loss increased to ($262.7) million, compared to a loss of ($203.5) million in 2013. MacDermid reported net income of $0.3 million, compared to a net loss of ($203.5) million in 2013.
  • Adjusted EBITDA in 2014 reached $212.2 million, up 17.8%, compared to $180.1 million in 2013. The MacDermid business contributed $196.2 million, up 8.9% compared to last year.
  • Adjusted EBITDA margin levels for the year were 25.2%, with MacDermid delivering an adjusted EBITDA margin of 26.0%. These levels represent significant increases compared to the adjusted EBITDA margin of 24.1% reported in 2013.
  • Adjusted net income attributable to common shareholders rose to $113.6 million in 2014 from $89.6 million in 2013.
  • Adjusted diluted earnings per share were $0.59, compared to $0.46 per adjusted diluted earnings per share in 2013.
  • Adjusted recurring free cash flow of $148.2 million, or $0.77 per adjusted diluted share, was 51.4% higher in 2014 compared to the $97.9 million, or $0.51 per adjusted diluted share, reported in 2013.

Daniel H. Leever, Platform's Chief Executive Officer, commented, "Our remarkable performance in 2014 continued into the fourth quarter. MacDermid delivered record top- and bottom-line results and both CAS and Agriphar added meaningful contributions. Importantly, we achieved these results in spite of currency headwinds and increased investments back into the business. With the Arysta acquisition —our third and largest AgroSolutions acquisition— completed we have expanded our leadership capabilities and have already accelerated our integration plans. Based on our progress in integration and integration planning in just the past month, we are revising our projected three-year synergy target upwards from $65 million to $80 million."

Frank J. Monteiro, Platform's Chief Financial Officer, added, "Throughout 2014 we built solid momentum and achieved record-level adjusted EBITDA, adjusted EBITDA margins, and adjusted non-GAAP free cash flow. In addition to growing our underlying business, in recent months we have financed and closed key acquisitions that are almost immediately accretive to our adjusted earnings. Moving forward, we are focused on maintaining a prudent capital structure so that we can meet our long-term leverage target, execute on our build-up strategy, and create value for our shareholders."

In the fourth quarter of 2014, Platform closed its acquisitions of the Agriphar Group ("Agriphar") and Chemtura AgroSolutions ("CAS") and announced its acquisition of Arysta LifeScience ("Arysta"). The Company also completed several financings related to these transactions including a $650 million private placement of common shares, $402 million registered equity offering, and two term loan deals for an aggregate of approximately $700 million.

Wayne Hewett, Platform's President, noted, "While it's evident that Platform took significant strides to establish a meaningful presence in the agrochemicals space in 2014, it's important to underscore the quality of the assets that we have acquired. CAS, Agriphar, and Arysta all delivered record EBITDA levels in 2014 demonstrating the strength of these individual businesses. We believe that combining the three will yield a powerful offering in terms of product portfolio, crop exposure, and geographic reach that will help us accelerate growth and ultimately drive cash flow generation."

The Company has presented both US GAAP and adjusted financials to better provide investors with measures that allow them to more readily compare the performance of the Company. These adjusted amounts will provide investors insight into the cash generated from operations after taking into consideration reinvestment in the business for Free Cash Flow, Recurring Free Cash Flow, and Adjusted EBITDA.

Conference Call

Platform will host a webcast/dial-in conference call to discuss its fourth quarter and full year 2014 financial results at 8:00 a.m. (Eastern Time) on Wednesday, March 18, 2015. Participants on the call will include Daniel H. Leever, Chief Executive Officer, Wayne Hewett, President, and Frank J. Monteiro, Chief Financial Officer.

To listen to the call by telephone, please dial (855) 357-3116 (domestic) or (484) 365-2867 (international) and provide the Conference ID: 82833025. The call will be simultaneously webcast at  www.platformspecialtyproducts.com . A replay of the call and webcast will be available for three weeks shortly after completion of the live call at  www.platformspecialtyproducts.com .

About Platform

Platform is a global producer of high-technology specialty chemicals and provider of technical services. The business involves the manufacture of a broad range of specialty chemicals, created by blending raw materials, and the incorporation of these chemicals into multi-step technological processes. These specialty chemicals and processes are sold into multiple industries including agricultural, electronics, graphic arts, metal and plastic plating, and offshore oil production and drilling. More information on Platform is available at www.platformspecialtyproducts.com .

Forward-Looking Statements

This release is intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995 as it contains "forward-looking statements" within the meaning of the federal securities laws, which include statements regarding Platform's adjusted earnings per share, expected or estimated revenue, the outlook for Platform's markets and the demand for its products, estimated sales, segment earnings, net interest expense, income tax provision, restructuring and other charges, cash flows from operations, consistent profitable growth, free cash flow, future revenues and gross operating and adjusted EBITDA margin improvement requirement and expansion, organic net sales growth, bank debt covenants, the success of new product introductions, growth in costs and expenses, the impact of commodities and currencies and Platform's ability to manage its risk in these areas, and the impact of acquisitions, divestitures, restructuring and other unusual items, including Platform's ability to successfully complete as well as integrate and obtain the anticipated results and synergies from its consummated and future acquisitions . These projections and statements are based on management's estimates and assumptions with respect to future events and financial performance, and are believed to be reasonable, though are inherently difficult to predict. Actual results could differ materially from those projected as a result of certain factors. A discussion of factors that could cause results to vary is included in Platform's periodic and other reports filed with the Securities and Exchange Commission, including Platform's annual report on Form 10-K for the fiscal year ended December 31, 2013 and quarterly reports on Form 10-Q for the fiscal quarters ended June 30, 2014 and September 30, 2014. Platform undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

—FINANCIAL TABLES TO FOLLOW—

PLATFORM SPECIALTY PRODUCTS CORPORATION
CONSOLIDATED BALANCE SHEETS
 
 
($ In thousands)
 
  December 31, 2014 December 31, 2013
     
Assets    
Cash & cash equivalents  $ 397,280  $ 123,040
Restricted cash  599,946  --
Accounts receivable, net of allowance for doubtful accounts of $9,598 and $10,113 at December 31, 2014 and December 31, 2013, respectively  327,346  140,525
Inventories  205,843  89,618
Prepaid expenses & other current assets  47,954  30,269
Total current assets  1,578,369  383,452
     
Property, plant & equipment, net  174,958  136,166
Goodwill  1,405,294  989,808
Intangible assets, net  1,341,480  720,302
Other assets  57,420  30,426
Total assets  4,557,521  2,260,154
     
Liabilities & Stockholders' Equity    
Accounts payable  106,671  56,156
Accrued salaries, wages and employee benefits  31,319  22,656
Current portion of long-term debt   15,071  7,958
Accrued income taxes payable  16,668  6,669
Accrued acquisition payable  14,278  --
Accrued expenses and other current liabilities  58,596  26,234
Total current liabilities  242,603  119,673
     
Long-term debt  1,400,823  744,291
Long-term deferred income taxes  202,292  169,800
Long term contingent consideration  63,900  34,800
Long term retirement plans  38,845  25,129
Other long-term liabilities  56,460  30,387
Total liabilities   2,004,923  1,124,080
     
Commitments and contingencies     
Redeemable 401(k) plan interest  --  20,972
   --  --
Stockholders' Equity    
Preferred shares (2,000,000 designated as Series A), 5,000,000 shares authorized at December 31, 2014 and December 31, 2013, respectively; 2,000,000 shares issued and outstanding at December 31, 2014 and December 31, 2013  20  --
Common shares, 400,000,000 shares authorized, 182,066,980 and 103,571,941 shares issued and outstanding at December 31, 2014 and 2013, respectively  1,901  --
Additional paid-in capital  2,812,375  1,212,038
Accumulated deficit  (224,130)  (194,222)
Accumulated other comprehensive (loss) income  (130,565)  1,265
Total stockholders' equity  2,459,601  1,019,081
Income in non-controlling interest  92,997  96,021
Total equity  2,552,598  1,115,102
     
Total liabilities, redeemable 401(k) interest and stockholders' equity $ 4,557,521 $ 2,260,154
     
PLATFORM SPECIALTY PRODUCTS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
 
($ In thousands)
 
    Period from  
  For the Inception For the ten
  year ended  (April 23, 2013) through months ended 
  December 31, 2014 December 31 2013 October 31, 2013
  Successor Successor Predecessor
       
Cash flows from operating activities:      
Net (loss) income  $ (24,202)  $ (195,625)  $ 13,514
Adjustments to reconcile net (loss) income from operations to net cash flows provided by operating activities:      
Non-cash charge related to preferred stock dividend rights  --  172,006  --
Depreciation and amortization  87,950  12,778  32,835
Deferred income taxes  (43,176)  (7,481)  (4,845)
Non-cash fair value adjustment to contingent consideration  29,100  (700)  --
Manufacturer's profit in inventory adjustment  35,514  23,912  --
Loss on extinguishment of debt  --  --  18,788
Restructuring charges  1,478  762  3,636
Equity compensation expense  1,293  542  9,317
Other, net   4,424  (585)  3,545
       
Changes in assets & liabilities, net of acquisitions:      
Accounts receivable  4,922  6,222  (11,345)
Inventories  11,369  2,090  (4,612)
Accounts payable  10,885  (193)  2,367
Accrued expenses  (15,660)  (8,719)  3,915
Other assets and liabilities  (5,734)  2,514  (11,053)
Net cash flows provided by operating activities  98,163  7,523  56,062
       
Cash flows from investing activities:      
Capital expenditures  (18,547)  (2,263)  (8,931)
Proceeds from sale of non-financial assets  602  4,393  2,133
Purchases of marketable securities  --  (359,934)  --
Redemption of marketable securities  --  359,934  --
Cash restricted to fund acquisition  (599,946)  --  --
Acquisition of businesses, net  (1,361,852)  (922,361)  --
Other, net  (3,033)  --  (1,017)
Net cash flows used in investing activities  (1,982,776)  (920,231)  (7,815)
       
Cash flows from financing activities:      
Proceeds from issuance of debt, net of discount and fees  678,828  200  1,109,513
Repayments of borrowings  (9,102)  (2,180)  (732,873)
Repurchase of Predecessor Series A preferred stock  --  --  (270,167)
Advance from Platform Acquisition Holdings Limited  --  --  33,268
Proceeds from issuance of common stock, net   1,512,587  1,019,491  --
Payment of accumulated dividends on Series A preferred stock  --  --  (229,833)
Proceeds from issuance of preferred stock, net  --  20,000  --
Payment of debt financing fees  (13,172)  (1,830)  (13,589)
Other, net  (198)  (25)  (559)
Net cash flows provided by (used in) financing activities  2,168,943  1,035,656  (104,240)
       
Effect of exchange rate changes on cash and cash equivalents  (10,090)  92  (303)
       
Net increase (decrease) in cash and cash equivalents  274,240  123,040  (56,296)
       
Cash and cash equivalents at beginning of period  123,040  --  143,351
Cash and cash equivalents at end of period  $ 397,280  $ 123,040  $ 87,055
       
Noncash Investing Activities      
Unpaid capital expenditures included in accounts payable and accrued expenses  2,373  --  --
       
PLATFORM SPECIALTY PRODUCTS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
 
 
($ In thousands)
 
    Period from    
    Inception For the ten  
  Year Ended (April 23, 2013) through months ended  Year Ended
  12/31/2014 December 31, 2013 October 31, 2013 12/31/2012
  Successor Successor Predecessor Predecessor
         
Net sales  $ 843,186  $ 118,239  $ 627,712  $ 731,220
Cost of sales  446,633  82,587  304,875  376,166
Gross profit  396,553  35,652  322,837  355,054
         
Operating expenses:        
Selling, technical, general and administrative  357,872  54,521  207,554  214,614
Non-cash charge related to preferred stock dividend rights  --  172,006  --  --
Research and development  26,229  3,995  19,898  25,051
Restructuring  2,955  762  3,636  292
Total operating expenses  387,056  231,284  231,088  239,957
         
Operating profit (loss)  9,497  (195,632)  91,749  115,097
         
Other (expense) income:        
Interest, net  (37,902)  (5,372)  (45,929)  (49,139)
Loss on extinguishment of debt  --  --  (18,788)  --
Other (expense) income, net  (2,484)  (440)  (557)  4,981
   (40,386)  (5,812)  (65,274)  (44,158)
(Loss) income before income taxes, non-controlling interests and dividends on preferred shares   (30,889)  (201,444)  26,475  70,939
Income tax benefit (provision)  6,687  5,819  (12,961)  (24,673)
Net (loss) income  (24,202)  (195,625)  13,514  46,266
Net income attributable to the non-controlling interests  (5,706)  1,403  (295)  (289)
         
Net (loss) income attributable to shareholders  (29,908)  (194,222)  13,219  45,977
         
Accrued stock dividend on Founder's preferred shares  (232,747)  --  --  --
Accrued payment-in-kind dividend on cumulative preferred shares  --  --  (22,454)  (44,605)
Net (loss) income attributable to common shares  $ (262,655)  $ (194,222)  $ (9,235)  $ 1,372
         
Earnings (loss) per share        
Basic  $ (1.94)  $ (2.10)  n/a   n/a 
Diluted  $ (1.94)  $ (2.10)  n/a   n/a 
         
Weighted average shares outstanding (In thousands)        
Basic  135,305  92,563  n/a   n/a 
Diluted  135,305  92,563  n/a   n/a 
         
PLATFORM SPECIALTY PRODUCTS CORPORATION
NON-GAAP AS ADJUSTED INCOME STATEMENTS 
FOR THE THREE MONTHS ENDED DECEMBER 31, 2014 AND 2013
 
 
(In thousands, except per share amounts)
  Three Months Ended
December 31, 2014
Adjustments
2014
  As Adjusted
Three Months Ended
December 31, 2014
  Combined (1)
Three Months Ended
December 31, 2013
Adjustments
2013
  As Adjusted
Three Months Ended
December 31, 2013
 
  Successor     Successor            
                     
Net sales  $ 273,545  $ --    $ 273,545    $ 185,394  $ --    $ 185,394  
Cost of sales  161,125  (23,558) a  137,567    115,732  (24,191)  a   91,541  
Gross profit  112,420  23,558    135,978    69,662  24,191    93,853  
                     
Operating expenses:                    
Selling, technical, general and administrative  126,135  (56,712) b,c,d  69,423    92,800  (49,431)  b,c,e   43,369  
Non-cash charge related to preferred stock dividend rights  --  --    --    172,006  (172,006)  f   --  
Research and development  7,765  --    7,765    6,389  --    6,389  
Restructuring  1,984  (1,984)    --    2,508  (2,508)    --  
Total operating expenses  135,884  (58,696)    77,188    273,703  (223,945)    49,758  
                     
Operating (loss) profit  (23,464)  82,254    58,790    (204,041)  248,136    44,095  
                     
Other income (expense):                    
Interest, net  (14,527)  --    (14,527)    (10,686)  --    (10,686)  
Other income (expense)  1,186  (2,295) g  (1,109)    (593)  (911)  g   (1,504)  
   (13,341)  (2,295)    (15,636)    (11,279)  (911)    (12,190)  
(Loss) income before income taxes, non-controlling interests and dividends on preferred shares   (36,805)  79,959    43,154    (215,320)  247,225    31,905  
Income tax benefit (provision)  3,145  (18,565) h  (15,420)    13,789  (25,164)  h   (11,375)  
Net (loss) income   (33,660)  61,394    27,734    (201,531)  222,061    20,530  
Net income attributable to the non-controlling interests  (326)  345 i  19    1,428      1,428  
                     
Net (loss) income attributable to shareholders  (33,986)  61,739    27,753    (200,103)  222,061    21,958  
                     
Accrued stock dividend on Founder's preferred shares  (232,747)  232,747 j  --    --        
Accrued payment-in-kind dividend on cumulative preferred shares  --  --    --    --    k   --  
Net (loss) income attributable to common shares  $ (266,733)  $ 294,486    $ 27,753    $ (200,103)  $ 222,061    $ 21,958  
                     
Earnings (loss) per share                    
Basic  $ (1.59)  --    $ 0.17    --  --    $ 0.13  
Diluted  $ (1.59)  --    $ 0.14    --  --    $ 0.11  
                     
Weighted average shares outstanding                     
Basic  167,480  --    167,480    --  --    167,480  l 
Diluted  167,480  --    193,100  m   --  --    193,100  m 
                     
                     
a Adjustment to reverse manufacturer's profit in inventory purchase accounting adjustment associated with Chemtura and Agriphar Acquisitions in Q4 2014 and MacDermid in Q4 2013. 
 
b Includes $29.5 million in Q4 2014 and $32.1 million in Q4 2013 for costs primarily associated with the Chemtura, Arysta and Agriphar Acquisitions.
 
c Includes $23.8 million in Q4 2014 and $11.1 million in Q4 2013 for intangible amortization expense that is added back in the "As Adjusted" Income Statement.
 
d Adjustment to reverse contingent consideration fair value adjustment of $3 million in connection with the MacDermid Acquisition.
 
e Adjustment for predecessor stock compensation and long term incentive plan expense included in operating expenses of $9.3 million.
 
f Non-cash charge related to preferred stock dividend rights over adjusted out of operating expenses.
 
g Adjustment to reverse net mark-to-market gain on foreign exchange forward contracts entered into to finance Chemtura and Agriphar Acquisitions in Q4 2014. Adjustment to eliminate gain on sale of building in Q4 2013.
 
h Adjustment to calculation of estimated effective tax rate of 36% in Q4 2014 and 36% in Q4 2013.
 
i Adjustment for reversal of the income attributable to the non-controlling interest resulting from the MacDermid Acquisition.
 
j Reversal of accrued stock dividend to Founders issued in January 2015.
 
k Reversal of accrued accretion on Predecessor preferred stock dividends that were not paid until the MacDermid Acquisition.
 
l Weighted average basic shares for Q4 2014 are being used for Q4 2013 for comparison.
 
m Non-GAAP Diluted Shares are calculated as follows:
                     
Outstanding shares at December 31, 2014 (excl. Founders Stock Dividend)  182,067                  
Conversion of exchange rights held by selling stockholders of MacDermid  8,641                  
Common shares equivalent of founder's preferred shares  2,000                  
Vested Director stock options  250                  
Equity awards granted in 2014  142                  
Adjusted Diluted shares at December 31, 2014  193,100                  
                     
(1) For the quarter ended December 31, 2013, adjustments to net income included combining predecessor (MacDermid) results for the period from October 1, 2013 through October 31, 2013 with the Company's results as Platform did not own MacDermid for any of the predecessor period or for the entirety of the successor period. The successor period reflects Platform's new accounting basis as of the MacDermid acquisition and combined results are presented for comparative purposes.
                     
PLATFORM SPECIALTY PRODUCTS CORPORATION
NON-GAAP AS ADJUSTED INCOME STATEMENTS 
FOR THE YEAR ENDED DECEMBER 31, 2014 AND 2013
 
 
(In thousands, except per share amounts)
  Year Ended
December 31, 2014
Adjustments
2014
  As Adjusted
Year Ended
December 31, 2014
  Combined (1)
Year Ended
December 31, 2013
Adjustments
2013
  As Adjusted
Year Ended
December 31, 2013
 
  Successor     Successor            
                     
Net sales  $ 843,186  $ --    $ 843,186    $ 745,951  $ --    $ 745,951  
Cost of sales  446,633  (35,514) a  411,119    387,463  (24,192)    363,271  
Gross profit  396,553  35,514    432,067    358,488  24,192    382,680  
                     
Operating expenses:                    
Selling, technical, general and administrative  357,872  (145,372) b,c,d  212,500    262,076  (69,602)  c   192,474  
Non-cash charge related to preferred stock dividend rights  --  --    --    172,006  (172,006)  e     
Research and development  26,229  --    26,229    23,893  (290)    23,603  
Restructuring  2,955  (2,955)    --    4,398  (4,398)    --  
Total operating expenses  387,056  (148,327)    238,729    462,373  (246,296)    216,077  
                     
Operating profit (loss)  9,497  183,841    193,338    (103,885)  270,488    166,603  
                     
Other income (expense):                    
Interest, net  (37,902)  --    (37,902)    (51,300)  21,031  f   (30,269)  
Loss on extinguishment of debt  --  --    --    (18,788)  18,788  g   --  
Other (expense) income  (2,484)  842 h  (1,642)    (996)  (1,143)  h   (2,139)  
   (40,386)  842    (39,544)    (71,084)  38,676    (32,408)  
(Loss) income before income taxes, non-controlling interests and dividends on preferred shares   (30,889)  184,683    153,794    (174,969)  309,164    134,195  
Income tax benefit (provision)  6,687  (46,717) i  (40,030)    (7,142)  (37,142)  i   (44,284)  
Net (loss) income  (24,202)  137,966    113,764    (182,111)  272,022    89,911  
Net income attributable to the non-controlling interests  (5,706)  5,503 j  (203)    1,108  (1,434)    (326)  
                     
Net (loss) income attributable to shareholders  (29,908)  143,469    113,561    (181,003)  270,588    89,585  
                     
Accrued stock dividend on Founder's preferred shares  (232,747)  232,747 k  --    --  --    --  
Accrued payment-in-kind dividend on cumulative preferred shares  --  --    --    (22,454)  22,454  l   --  
Net (loss) income attributable to common shares  $ (262,655)  $ 376,216    $ 113,561    $ (203,457)  $ 293,042    $ 89,585  
                     
Earnings (loss) per share                    
Basic  $ (1.94)  --    $ 0.84    --  --    $ 0.66  
Diluted  $ (1.94)  --    $ 0.59    --  --    $ 0.46  
                     
Weighted average shares outstanding                     
Basic  135,305  --    135,305    --  --    135,305  m 
Diluted  135,305  --    193,100  n   --  --    193,100  n 
                     
                     
a Adjustment to reverse manufacturer's profit in inventory purchase accounting adjustment associated with MacDermid, Chemtura and Agriphar Acquisitions. 
 
b Includes $47.8 million in 2014 for costs primarily associated with Chemtura, Arysta and Agriphar Acquisitions.
 
c Includes $67.4 million in 2014 and $31.3 million in 2013 for intangible amortization expense that is added back in the "As Adjusted" Income Statement.
 
d Adjustment to reverse contingent consideration fair value adjustment of $29.1 million in connection with the MacDermid Acquisition.
 
e Non-cash charge related to preferred stock dividend rights over adjusted out of operating expenses.
 
f Adjustment to eliminate interest associated with debt not assumed with the MacDermid Acquisition.
 
g Adjustment to eliminate extinguishment of debt associated with recapitalization of MacDermid in Q2 2013.
 
h Adjustment primarily to reverse net mark-to-market loss on foreign exchange forward contracts entered into to finance Chemtura and Agriphar Acquisitions in 2014. Reversal of non-cash, mark-to-market gains on foreign debt in 2013.
 
i Adjustment to calculation of estimated blended effective tax rate of 26% in 2014 and 33% in 2013
 
j Adjustment for reversal of the income attributable to the non-controlling interest resulting from the MacDermid Acquisition.
 
k Reversal of accrued stock dividend to Founders issued in January 2015.
 
l Reversal of accrued accretion on Predecessor preferred stock dividends that were not paid until the MacDermid Acquisition.
 
m Weighted average basic shares for 2014 are being used for 2013 for comparison.
 
n Non-GAAP Diluted Shares are calculated as follows:
                     
Outstanding shares at December 31, 2014 (excl. Founders Stock Dividend)  182,067                  
Conversion of exchange rights held by selling stockholders of MacDermid  8,641                  
Common shares equivalent of founder's preferred shares  2,000                  
Vested Director stock options  250                  
Equity awards granted in 2014  142                  
Adjusted Diluted shares at December 31, 2014  193,100                  
                     
(1) For the year ended December 31, 2013, adjustments to net income included combining predecessor (MacDermid) results for the period from January 1, 2013 through October 31, 2013 with the Company's results as Platform did not own MacDermid for any of the predecessor period or for the entirety of the successor period. The successor period reflects Platform's new accounting basis as of the MacDermid acquisition and combined results are presented for comparative purposes.
                     
PLATFORM SPECIALTY PRODUCTS CORPORATION
RECONCILIATION OF NON-GAAP MEASURES
Includes Predecessor and Successor data
  Combined Successor Combined Successor  
(in millions) Q4 2013 Q4 2014 YTD 2013 YTD 2014  
Net loss  $ (200.1)  $ (34.0)  $ (181.0)  $ (29.9)  
           
Adjustments to reconcile to net loss:           
Income tax (benefit) expense  (13.8)  (3.1)  7.1  (6.7)  
Interest expense  10.8  14.9  51.8  38.7  
Depreciation and amortization expense  16.2  30.7  45.6  88.0 (1)
Equity based compensation expense  9.6  0.5  9.6  1.3 (2)
Restructuring and related expenses  2.5  2.0  8.0  3.0 (3)
Non cash charges related to Founder Preferred Dividend  172.0  --   172.0  --  (4)
Predecessor loss on extinguishment of debt  --   --   18.8  --  (5)
Manufacturer's profit in inventory adjustment  23.9  23.6  23.9  35.5 (6)
Non-cash fair value adjustment to contingent consideration  --   3.0  --   29.1 (7)
Acquisition Costs  32.1  29.5  32.1  47.8 (8)
Other expense (income)  (8.7)  (1.4)  (7.8)  5.4 (9)
           
Adjusted EBITDA   $ 44.5  $ 65.7  $ 180.1  $ 212.2  
           
           
Footnotes:
(1) Includes $23.8 million in Q4 2014 and $11.1 million in Q4 2013 and $67.4 million in YTD 2014 and $31.3 million in YTD 2013 for amortization expense that is added back in the "As Adjusted" Income Statement.
(2) Adjustment for predecessor stock compensation and long term incentive plan expense.
(3) Includes restructuring expenses of $1.9 million of reorganization costs adjusted out of operating expenses for YTD 2013.
(4) Non-cash charge related to preferred stock dividend rights.
(5) Adjustment to eliminate extinguishment of debt associated with recapitalization of MacDermid in Q2 2013.
(6) Adjustment to reverse manufacturer's profit in inventory purchase accounting adjustment associated with MacDermid Acquisition for YTD 2013 and Chemtura and Agriphar Acquisitions for YTD 2014 
(7) Adjustment to fair value of contingent consideration in connection with the MacDermid Acquisition primarily associated with achieving the share price targets.
(8) Adjustment to reverse deal costs primarily in connection with the MacDermid Acquisition for YTD 2013 and the Chemtura, Arysta and Agriphar Acquisitions for YTD 2014.
(9) Adjustment for 2014 primarily for reversal of the income attributable to the non-controlling interest resulting from the MacDermid Acquisition. For 2013, adjustment to reverse miscellaneous non-recurring charges.

Source/Investor Relations Contact: Benjamin Gliklich Vice President, Corporate Development, Finance and Investor Relations Platform Specialty Products Corporation +1-561-406-8465 Media Contacts: Liz Cohen Weber Shandwick +1-212-445-8044 Kelly Gawlik Weber Shandwick +1-212-445-8368

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 88

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 83

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading

Top 5 Most Recently Viewed Articles

Nukkleus Stock Skyrockets 16% After Major Decision

Updated Category News Views 330

Nukkleus Inc. Stock Soars in After-Hours Trading Nukkleus Inc. (NASDAQ: NUKK) is making headlines as its shares have surged during after-hours trading following important developments within the company. This noteworthy stock movement reflects both investor sentiment and strategic changes that the company is undergoing. After-Hours Rally Sparks Investor Interest In recent...

Continue Reading
Tambourine One Revolutionizes Hotel Booking Experiences

Updated Category News Views 135

Introducing Tambourine One: A New Era in Hotel Booking Tambourine, the renowned leader in hotel marketing technology, has launched an innovative product known as Tambourine One. This all-in-one solution merges their advanced website technology with a booking engine, aimed at boosting direct bookings for hotels and resorts. By enhancing the booking process, Tambourine One...

Continue Reading
Midwest Great Dane: A New Era for Trudell Trailer Sales

Updated Category News Views 217

Midwest Great Dane Reveals Brand Transformation Midwest Great Dane, previously known as Trudell Trailer Sales, is making waves in the transportation and trucking industry with its recent name change. This transformation stems from a strategic acquisition by Cox Automotive, aimed at enhancing their representation of the Great Dane brand in the Midwest. The organization's...

Continue Reading
SoftServe Launches New Partner Unit to Boost AI Solutions

Updated Category News Views 334

SoftServe Unveils New Partner Business Unit for Enhanced AI Services SoftServe has officially launched its first dedicated Partner Business Unit (BU), marking a significant step forward in its strategic partnership with Microsoft. This initiative is designed to leverage SoftServe's extensive experience in technology and digital services, ensuring that organizations can...

Continue Reading
Portugal's Agri-Food Push in Canada: A Taste for Growth

Updated Category News Views 52

Eyeing Fresh Opportunities in Canada Here's a hot one for you—Portugal's agri-food sector is making a notable splash over in Canada. Yeah, you heard it right. Amidst the hustle and bustle of the SIAL Canada, which isn't just any minor shindig, "Taste & Feel Portugal 2.0" aims to put Portugal's top-tier grub on the map. It's about more than nibbling on cheese; it's a...

Continue Reading